Gemcitabine continuation maintenance therapy had a favourable ICER in patients with PS = 0 ( 52,213 / QALY ) , in responders to induction chemotherapy ( 64,296 / QALY ) , regardless of histology ( adenocarcinoma , 62,292 / QALY , non adenocarcinoma , 83,291 / QALY ) .